Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TRL1068 in Subjects With Acute Exacerbation of Chronic Rhinosinusitis
Latest Information Update: 14 Apr 2023
At a glance
- Drugs TRL 1068 (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Trellis Bioscience
Most Recent Events
- 10 Apr 2023 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 10 Apr 2023 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 10 Apr 2023 Planned initiation date changed from 1 Jan 2023 to 1 Jan 2024.